CALA - Calithera Biosciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Calithera Biosciences, Inc.

343 Oyster Point Boulevard
Suite 200
South San Francisco, CA 94080
United States
(650) 870-1000

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Dr. Susan M. Molineaux Ph.D.Founder, CEO, Pres & Director625.81kN/A1954
Ms. Stephanie WongCFO & Sec.752.42kN/A1974
Dr. Christopher J. Molineaux Ph.D.Sr. VP of Devel.N/AN/A1953
Mr. Frank Parlati Ph.D.Sr. VP of ResearchN/AN/A1969
Dr. Susan B. Demo Ph.D.Sr. VP of R&D OperationsN/AN/AN/A
Dr. Allison Dillon Ph.D.Sr. VP of Commercial & Portfolio StrategyN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Corporate Governance

Calithera Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.